Beta-adrenergic antagonists might play an even larger role in modulating neuroinflammation in PD via the suppression of cyclooxygenase 2 (COX2), which is reportedly increased in the substantia nigra of PD patients [8]. Here, PTGS2 is linked to Parkinson disease.